ReviewESC heart failure2022
Obesity and contraceptive use: impact on cardiovascular risk.
Review in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacokinetics of Drospirenone Only Pills in Obese Thai Women: A Pre- and Post-Bariatric Surgery Study
Drospirenone Only Pills and Cervical Mucus Changes in Obese Thai Women: A Pre- and Post-Bariatric Surgery Study
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Diagnosis and management of polycystic ovary syndrome/polyendocrine metabolic ovarian syndrome: unmet needs and areas of clinical confidence among European endocrinologists.Journal of endocrinological investigation · 2026Article
- Current Body Mass Index Is Associated with Reported Weight Gain as a Reason for Discontinuing Oral Contraceptive Pill Use.Obesities · 2026Article
- Review
- Cardiovascular risk profile according to World Health Organization medical eligibility criteria for contraceptive use of women using hormonal contraception in Rio de Janeiro state, Brazil.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- Article
- Article
- Estrogen and obesity synergistically suppress protein S via HIF1α, enhancing thrombosis potential.The Journal of clinical investigation · 2025Article
- Venous thromboembolism in obese hormonal contraceptive users: a large national database study.Research and practice in thrombosis and haemostasis · 2025Article
- Detection of Problems Related to Hormonal Contraceptives in Community Pharmacy: Application of a Structured Questionnaire in Women of Childbearing Age.Pharmacy (Basel, Switzerland) · 2025Article
- Moderate Associations Between the Use of Levonorgestrel-releasing Intrauterine Device and Metabolomics Profile.The Journal of clinical endocrinology and metabolism · 2025Article
- Navigating pregnancy with cardiovascular disease: pathophysiology, risk stratification, and maternal-fetal outcomes.Turkish journal of medical sciences · 2025Review
- PCOS and Obesity: Contraception Challenges.Open access journal of contraception · 2025Review
- Prevalence of Overweight, Obesity, and Abdominal Obesity in Polish Adults: Sociodemographic Analysis from the 2016-2020 National Health Program.Nutrients · 2024Article
- Standardized Data Elements for Patients With Acute Pulmonary Embolism: A Consensus Report From the Pulmonary Embolism Research Collaborative.Circulation · 2024Review
- Article
- Article
- Obesity, thrombosis, venous disease, lymphatic disease, and lipedema: An obesity medicine association (OMA) clinical practice statement (CPS) 2023.Obesity pillars · 2023Article
- Association between oral contraceptives with lipid profile: results from Hoveyzeh cohort study (HCS).BMC women's health · 2023Article
- Women's health, hormonal balance, and personal autonomy.Frontiers in medicine · 2023Review
- Obesity and contraceptive use: impact on cardiovascular risk.ESC heart failure · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and oestrogen containing contraceptive products are well-known independent cardiovascular risk factors. However, a significant number of obese women continue to receive prescriptions of hormonal products that contain oestrogens for their contraception. We have conducted a narrative review to discuss the latest evidence, ongoing research, and controversial issues on the synergistic effect of obesity and contraceptive use, in terms of cardiovascular risk. There is compelling evidence of an interplay between obesity and contraception in increasing cardiovascular risk. Women who present both obesity and use of combined oral contraceptives (COCs) have a greater risk (between 12 and 24 times) to develop venous thromboembolism than non-obese non-COC users. Data here discussed offer new insights to increase clinicians' awareness on the cardiovascular risk in the clinical management of obese women. The synergistic effect of obesity and COCs on deep venous thrombosis risk must be considered when prescribing hormonal contraception. Progestin-only products are a safer alternative to COCs in patients with overweight or obesity. Obese women taking contraceptives should be viewed as an 'at risk' population, and as such, they should receive advice to change their lifestyle, avoiding other cardiovascular risk factors, as a form of primary prevention. This indication should be extended to young women, as data show that COCs should be avoided in obese women of any age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.